This 60-minute on-demand webcast highlights important and practice-changing developments in gastrointestinal biomarker testing and treatment, including new clinical data with immediate implications for patient care. Using a case-based approach, an expert GI pathologist and oncologist will help you learn optimal testing, interpreting findings, individualized treatment, and sequencing strategies for gastrointestinal cancers.
Topics include:
1) Biomarkers and the use of molecular testing to guide therapy selection in patients with advanced colorectal, pancreatic, biliary, gastric, esophageal, and gastroesophageal junction cancers, such as:
· BRAF V600E, BRCA1/2, HER2/HER3, BRAF V600E, IDH1, and FGFR2
· Tumor agnostic biomarkers, such as MMR/MSI, NTRK, and TMB
· Emerging biomarkers
2) Emerging assays in GI cancers, such as liquid biopsy
This webcast includes case discussions, polling questions, and a Q&A session for you to get answers from the experts in real time.
The activity offers 1.0 CME/CMLE credit.
Learning Objectives:
Upon completion of this activity, you should be able to:
· Apply the available data and expert recommendations to determine which biomarkers should be assessed in patients with GI malignancies
· Implement best practices for molecular testing in GI cancers, including the use of tissue-based biomarker testing for evaluation of BRAF V600E, HER2/HER3, BRCA1/2, FGFR2, IDH1, and tumor agnostic markers
· Plan therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment to improve duration and quality of life
· Evaluate the clinical validity, utility, and differences among single biomarker companion diagnostics and available comprehensive genomic testing platforms using next-generation sequencing
· Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in GI malignancies for patient counsel and potential enrollment
Faculty:
Wei Jiang, MD, PhD
Associate Professor
Director, Translational Research/Pathology
Shared Resource of Sidney Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA
Atrayee Basu-Mallick, MD
Associate Professor
Medical Oncology
Jefferson Health/Jefferson University Hospitals
Philadelphia, PA
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)â„¢. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this enduring material for a maximum of 1.0 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time
Method of Participation
To complete the activity and receive credit, the participant must complete the online course. CME certificates will be provided on-line.
Provided by American Society of Clinical Pathology and Clinical Care Options, LLC.
Supported by educational grants from Pfizer Inc. and Seagen Inc.